Fast Market Research

New Market Report: Market Access Impact: Renal Cell Carcinoma (EU5)

Fast Market Research announces the availability of the new FirstWord Pharma report, "Market Access Impact: Renal Cell Carcinoma (EU5)", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 06/13/2016 -- Market barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand one of them?

We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European market when oncologists can't prescribe freely. The result: 5 of those brands saw a net loss.

But 3 of them made significant net gains. Is your brand one of them?

You'll learn how market barriers affect share for 8 major treatments from Bayer/Amgen, Novartis, Pfizer, and Roche.

Plus you'll see which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.

Reasons to Get this Report

Get Answers to Key Questions about RCC Drug Brands

-Afinitor (everolimus; Novartis): Afinitor takes market share from only two brands. Which two?

-Avastin (bevacizumab; Roche): Which brand takes more than twice as much share from Avastin as any other?

-Inlyta (axitinib; Pfizer): Would eliminating market barriers help Inlyta catch up to Afinitor?

-Nexavar (sorafenib; Bayer/Amgen): Are doctors who don't prescribe either brand more likely to consider Nexavar or Inlyta?

-Proleukin (aldesleukin; Novartis): Which two barriers do more doctors experience with Proleukin than any other brand?

-Sutent (sunitinib; Pfizer): Which barrier is responsible for nearly a quarter of Sutent's impressive share gain?

-Torisel (temsirolimus; Pfizer): Only one market barrier earns Torisel a net share gain. Which one?

-Votrient (pazopanib; Novartis): Votrient and Afinitor are just about equally prescribed. Which brand has the edge in market share?

Get More Details on this Report and a Full Table of Contents at Market Access Impact: Renal Cell Carcinoma (EU5)

Top Takeaways

-Barriers cost most brands market share: Five of the eight surveyed brands saw a net share loss due to barriers. Only three saw net gains.

-Eliminating barriers would tighten up the market: Especially the top of the market, where it would make a big dent in the #1 brand's lead.

-Most brands are heavily prescribed: A majority of doctors prescribe nearly all of the brands surveyed. The most prescribed brand has almost a 10% lead over its nearest rival.

-Clear market share winner: of the three brands that gain share due to market barriers, one gains more than twice as much as the closest competitor.

-Barrier effect varies widely: The number of doctors who experience each market barrier varies widely from brand to brand.

-Reimbursement and guidelines have the greatest impact: barriers related to reimbursement, patient type restrictions, and guidelines affect more prescriptions than any others.

-Brand awareness is high: With one exception, no more than 1% of doctors surveyed were unaware of any given brand.

-Overall market access is good: In Europe, market barriers affect less than 20% of prescription decisions.

Exploring Market Access Issues

Market Access Impact: RCC explores key issues affecting RCC drug manufacturers. You'll learn:

How barriers affect market access:

-What brands do doctors prescribe the most?
-How many prescriptions do barriers affect?
-Which barriers have the biggest effect?

How barriers affect your brand:

-How many doctors prescribe your brand? How many don't, but would consider it?
-Why don't doctors prescribe your brand? What do they prescribe instead?
-Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 medical oncologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.

All respondents have:

-Been practicing for 2+ years
-Prescribed at least one of the listed products
-Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between April 4th and 11th, 2016.


At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-Market Access Impact: Renal Cell Carcinoma (US)
-NPS+ Renal Cell Carcinoma (EU5)
-Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
-NPS+ Renal Cell Carcinoma (US)
-Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H1 2015